VPS45 Deficiency Beyond Neutropenia: A Systematic Review of Genotype–Phenotype Correlations, Transplant Outcomes, and Duplicate Case Reporting

Background and Objective: VPS45 deficiency (severe congenital neutropenia type 5) is an ultra-rare autosomal recessive disorder associated with congenital neutropenia, progressive marrow fibrosis, recurrent infection, and multisystem disease. Since its molecular description in 2013, the recognized phenotype has expanded to include combined immunodeficiency, neurodevelopmental abnormalities, and hemophagocytic lymphohistiocytosis (HLH). Published evidence remains fragmented across case reports and sequential single-centre series, creating a particular risk of counting the same patient more than once. This review aims to define the reported genotypic and phenotypic spectrum, summarize hematopoietic stem cell transplantation (HSCT) outcomes, and explicitly resolve overlapping case reports to produce a clinically interpretable patient-level synthesis.

Methods: A systematic review protocol was developed in accordance with PRISMA 2020 principles and submitted for registration to PROSPERO; ethics approval was obtained for analysis of published, de-identified data. Eligible reports include case reports, case series, and conference abstracts describing molecularly confirmed biallelic VPS45 variants. Searches are designed for PubMed/MEDLINE, Embase, Scopus, Web of Science, and supplementary grey-literature sources without language restriction. Standardized patient-level extraction captures genotype, hematological and marrow findings, organ involvement, infections, treatment, HSCT, engraftment, survival, and neurological/immunological features. Because sequential publications frequently originate from the same centres, cases are classified as confirmed distinct, probable duplicates, or unresolved using explicit cross-publication clinical and genetic matching. Preliminary patient-level synthesis identified 28 reported case records published from 2013–2025: 26 confirmed distinct patients, one probable duplicate, and one case whose distinctness remains unresolved.

Learning Points Discussion: Preliminary synthesis demonstrates that VPS45 deficiency is broader than a congenital neutropenia–myelofibrosis syndrome. The recurrent p.Thr224Asn variant constitutes the largest reported genotype cluster and has, to date, been described in consanguineous Palestinian families, whereas p.Glu238Lys has been reported across Moroccan, Turkish, and Japanese kindreds and repeatedly associated with neurodevelopmental involvement. Additional rare homozygous and compound-heterozygous variants further expand the phenotype. Severe infection and death before transplantation remain prominent, while HSCT outcomes are heterogeneous: durable engraftment has been achieved with several marrow/peripheral-blood donor approaches, whereas graft failure has occurred, including after umbilical-cord-blood transplantation. Recent reports additionally support combined immunodeficiency, HLH/hyperinflammatory phenotypes, and neurological manifestations including developmental impairment, movement disorder, and intracranial calcification. Importantly, cross-publication reconciliation identified confirmed and probable duplicate reporting as well as internally inconsistent cumulative case counts. In an ultra-rare disease, even one duplicated patient can materially distort apparent genotype–phenotype associations and transplant outcomes. A deduplicated, certainty-graded patient-level synthesis may therefore provide a more reliable reference for diagnosis, counselling, and transplant planning while establishing a reproducible approach to case ascertainment in ultra-rare disorders.